Active, Not Recruiting

Trial ID CC-92480-MM-002 | NCT03989414

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Sorry, this study is no longer accepting new participants, but is still ongoing.

You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.

Check Your Eligibility

About This Trial
Key Eligibility Criteria

Summary

Phase 1/Phase 2
18+

Age Range
Active, Not Recruiting

Overview

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Key Eligibility Criteria

Inclusion Criteria

: • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:

Documented diagnosis of multiple myeloma (MM) and measurable disease
Documented disease progression during or after their last antimyeloma regimen
Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen

Exclusion Criteria

Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis
Known central nervous system (CNS) involvement with myeloma
Received immunosuppressive medication within the last 14 days of initiating study treatment
Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment Other protocol-defined inclusion/exclusion criteria apply

Additional Information *

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Study Arms

Experimental: Cohort A: CC-92480 with bortezomib and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Bortezomib, Dexamethasone

Study Arms

Experimental: Cohort C: CC-92480 with carfilzomib and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Carfilzomib

Study Arms

Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Bortezomib, Dexamethasone

Study Arms

Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Carfilzomib

Study Arms

Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Bortezomib, Dexamethasone

Study Arms

Experimental: Cohort H: CC-92480 with elotuzumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Elotuzumab

Study Arms

Experimental: Cohort I: CC-92480 with isatuximab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Isatuximab

Study Arms

Experimental: Cohort J: CC-92480 with elotuzumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Elotuzumab

Study Arms

Experimental: Cohort K: CC-92480 with isatuximab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Isatuximab

Study Arms

Experimental: Subcohort B1: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Daratumumab

Study Arms

Experimental: Subcohort B2: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Daratumumab

Study Arms

Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Daratumumab

Study Arms

Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Daratumumab

Study Arms

Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Daratumumab

Study Arms

Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone

ASSIGNED INTERVENTION

Drug: CC-92480, Dexamethasone, Daratumumab

Trial ID CC-92480-MM-002 | NCT03989414

Summary

Overview

Key Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you